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1. Introduction
Many people suffer from excessive sleepiness during the afternoon hours. In all human
individuals the alertness level decreases after the noon peak. This afternoon dip or "postpran‐
dial dip" is physiological. The alertness level rises again later in the afternoon and early
evening, reaching another peak at about 7 to 8 p.m. Obesity is a recognized public health
problem. It is a strong risk factor for type 2 diabetes and cardiovascular disease. Obesity is also
the strongest risk factor of obstructive sleep apnea. Nutritional factors are important also in
many other sleep disorders. Many patients with restless legs syndrome have low blood ferritin
levels. [1] Sleepy patients with hypersomnias should avoid rapidly absorbing carbohydrates
at daytime to minimize afternoon sleepiness. Adenosine is accumulating in the brain, notably
in the basal forebrain, during wake, increasing the sleep pressure. [2] Caffeine, the most
commonly used stimulant, is an adenosine receptor antagonist. During deep slow wave sleep
glucose is stored in the glial cells. [3, 4] The brain-gut relationship is important also in the sleep-
wake regulation, although well-done studies on that topic are still scarce.
Sleep disorders are a large and under-recognised problem in many parts of the world. The
international classification of sleep disorders (ICSD), the most frequent and often the most
severe are obstructive sleep apnoea (OSA), narcolepsy, restless legs syndrome (RLS), periodic
limb movement disorder, insomnia, parasomnias, circadian rhythm disorders including jet lag
and shift work, and sudden infant death syndrome. However, the major research focuses on
OSA, insomnia and RLS since they are among the most highly prevalent sleep disorders and
there are established links between them and other health conditions, which is the area where
the majority of costs are incurred. The health system costs of sleep disorders comprise the cost
of the sleep disorders themselves and the share of health costs from other conditions attributed
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to sleep disorders. The total European cost of brain disorders in 2010 was €798 billion [5],
headaches and sleep disorders, meanwhile, only cost 285 and 348 euros respectively [6]. “The
human brain is not only the site of our personality, thoughts, feelings and other human
characteristics; it is also the seat of many chronic disabling diseases. These diseases have not
received the attention that has been devoted to heart disease, cancer or AIDS, but in recent
years there has been a growing awareness of their importance” [5]. A growing body of evidence
indicates that free radical formation is a mediator of the excessive lipid peroxidation and cell
damage seen in neurological disorders [7]. Antioxidant vitamins and trace elements have been
shown to have biological activity in acting as scavengers for free radical’s delays the onset of
defined milestones in the development of a disease. Therefore, micronutrients such as
vitamins, minerals or trace elements are supported by evidence that it can delay deterioration
of the disease.
Different  nutritional  factors,  and  eating,  can  have  an  effect  on  the  CNS  by  different
mechanisms:  direct  nervous  connections  through  the  vagus  nerve  and  nucleus  tractus
solitarius,  humoral  effects,  affecting  absorption  of  different  molecules,  emotional  and
cognitive processes.
2. Substances involved in the sleep-wake regulation and food intake
Many different neurotransmitters, neuromodulators and hormones have an important role in
regulation of sleep and wakefulness, and in eating behaviour. These substances include (in
alphabetical order): acetylcholine, adenosine, alpha-MSH (alpha melanocyte-stimulating
hormone), cholecystokinin, dopamine, GABA, ghrelin, glutamate, glycine, insulin, histamine,
hypocretin (orexin), leptin, MCH (melanin-concentrating hormone), melatonin, norepinephr‐
ine, NPY (neuropeptide Y), prostaglandins, serotonin, somatotrophin and thyrotropin. Little
is known about the effect of vitamins and minerals on sleep. They will be discussed shortly
later in this review.
3. Neurotransmitters in the Enteric Nervous System (ENS)
The enteric nervous system (ENS) can be considered the body’s second brain with more than
100 million neurons of different types. Neural signals may be transmitted from gut to the CNS
by neural connection and by humoral mechanisms. The afferent fibers of the gut-brain neural
are vagal (parasympathetic) and (ortho)sympathetic. Different sensors respond also to
distension of stomach and contractions of the intestine. Chemical stimuli (e.g. spices), gut
hormones, neurotransmitters, neuromodulators, cytokines and inflammatory mediators
produced by the bacterial flora in the gut-are all important. In the brainstem most afferent
vagal fibers terminate on the nucleus tractus solitarius (NTS). There is a viscerotopic repre‐
sentation of different parts of the enteric system in the NTS. The NTS is in connection with
hypothalamus and amygdala, which also plays a role in regulation of hunger and satiety. We
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should not forget the emotional aspects of eating (smell, taste, and situational factors during
eating).
Cholecystokinin is secreted by duodenal and jejunal cells after eating food. CCK acts on vagal
neurons projecting to the brainstem, giving a signal of satiety inhibiting further need for eating.
Ghrelin is secreted when a person is hungry and it increases appetite. It acts on the hypothal‐
amus stimulating feeding, counteracting the inhibitory effects of leptin.
Leptin is manufactured mainly in fat cells in adipose tissue. Leptin counteracts the effects of
neuropeptide Y and inhibits secretion of alpha-MSH (alpha melanocyte-stimulating hormone).
Leptin decreases appetite and inhibits food intake contrary to ghrelin.
Alpha-MSH is in the arcuate nucleus in the brain where it acts to suppress appetite. Alpha-
MSH may have also some function in the sleep-wake regulation.
Serotonin is an important neurotransmitter in the central nervous system (CNS) with impor‐
tant effects on sleep-wake regulation. Serotonin also has an important role in regulation of the
gastrointestinal (GI) function through an interaction with the ENS. Up to 60-90 % of the total
body amount of serotonin is in the GI tract, and 2-20% of all enteric neurons express serotonin.
Stimulatory receptors include β-adrenoceptors, muscarinic and nicotinic Ach receptors and 5-
HT3 receptors. Inhibitory receptors include alpha2-adrenceptors, histamine H3, GABA-B,
adenosine A2, and 5-HT4 receptors. In the GI tract 5-HT is eliminated mainly by monoamine
oxidase metabolism. [8]
Hypocretin (orexin) was originally considered to be important especially in central control of
food intake [9, 10] but it is essential also in control of sleep and wakefulness. There are about
70 000 hypocretin neurons in the lateral hypothalamus. Narcolepsy, a central hypersomnia
with excessive daytime sleepiness and cataplexy, is characterized by destruction of the
hypocretin neurons. [11, 12] Hypocretin is involved also in energy homeostasis, nociception,
reward seeking behavior, and drug addiction. [13-19] In addition to brain, hypocretins are also
widely present in the gastrointestinal tract12 where they have a role in regulation of peristaltic
GI motility, and in gastric, intestinal and pancreatic secretions. The hypothalamic hypocretin
cells are intermingled with MCH neurons. Both hypocretin-and MCH-cells are glucose-
sensing neurons. Decrease of glucose increases activity of hypocretin neurons and decreases
activity of the MCH cells, producing wakefulness. Respectively, increase of glucose decreases
activity of hypocretin and increases activity of MCH, producing sleepiness. These interactions
explain at least partly the alerting effects of fasting and the observations that eating rapidly
absorbing carbohydrates, provoking fast increase of blood glucose, increase sleepiness.
4. Caffeine and sleep
Coffee is the world’s most common psychoactive drug. Coffee includes caffeine, which is also
present in coffee, tea, cola and chocolate. The stimulant and wake-producing properties of
caffeine depend on its ability to reduce adenosine transmission in the brain. Caffeine acts as
an antagonist to adenosine A1 and especially to adenosine A2 receptors. [20, 13]
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In experimental studies the concentration of adenosine is higher during wakefulness than
during sleep, it accumulates in the brain during prolonged wakefulness, and local perfusions
as well as systemic administration of adenosine and its agonists induce sleep and decrease
wakefulness.2, 18 Supportive findings have been observed in humans. The longer the previous
wakefulness period is, the longer and deeper is the following sleep. [22] The increase in
extracellular adenosine concentration decreases the activity of the wakefulness-promoting cell
groups, especially the cholinergic cells in the basal forebrain. [2, 22]
In addition to coffee caffeine is found in tea (20-100 mg per 3.5 dl cup of tea), Cola-drinks (30-50
mg per 3.3 dl bottle), energy drinks and chocolate. In chocolate also theobromine is present in
large quantities. Dark chocolate is stimulating and 100 grams of 70% chocolate corresponds to
1-2 cups of coffee depending on strength of the coffee and size of the cup.
One small cup (30 ml) of espresso contains 30-50 mg of caffeine, and one large cup (2-4 dl) of
ordinary coffee contains 75-150 mg of caffeine. Caffeine is absorbed rapidly and the peak of
action occurs in 30 to 60 minutes. The duration of action is usually 4 to 6 hours, but in elderly
subjects with slower metabolism the duration may last up to more than 16 hours. A large
amount of caffeine, usually over 300-500 mg, i.e. more than 4 to 8 cups of coffee, depending
on individual sensitivity, causes restlessness, anxiety, trembling, tinnitus and feelings of
euphoria / delirium. Everyday use of more than 500 mg caffeine leads to caffeinism with
insomnia, fatigue, and different psychosomatic symptoms. Some chronic coffee drinkers have
developed tolerance to caffeine, and may drink more than 10 cups of coffee daily. They have
withdrawal symptoms if they do not have their coffee.
Coffee is a well-known factor disturbing sleep. [23-31]Two or three cups (or in sensitive
persons just one cup of coffee) in the evening is followed by difficulty falling asleep and restless
sleep. Insomniacs are usually advised to avoid coffee after 6 p.m. but in some sensitive persons
with insomnia coffee at noon or early afternoon may disturb falling asleep in the evening. It
is important to recognize that energy drinks such as Battery and Red Bull contain large
amounts of caffeine, which is a known cause for insomnia in adolescents. [31] Paradoxically,
in some persons one or two cups of coffee may ameliorate quality of sleep. The reason can be
behavioral conditioning, but it is also known that caffeine is inotropic and it stimulates
respiratory functions.
5. Neurohormetic phytochemicals
Mediterranean diets rich in fibres, vegetables, fruits and olive oils are associated with reduced
risk of cardiovascular disease and many neurological diseases. [32-34]Some effects are
explained by antioxidative effects of different phytochemicals, but there is also evidence that
some effects may be due to subtoxic effects of some neurotoxic molecules in the gut.
Hormesis is the paradoxical, stimulatory or beneficial action of toxins. Hormetic effects explain
why, sometimes, low doses of a given toxic substance, or radiation, may induce beneficial
effects while larger doses of the same substance or radiation are toxic to cells and organisms.
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[35, 36] Examples of endogenous molecules with neurohormetic actions are nitric oxide, carbon
monoxide, glutamate and calcium. Examples of neuroprotective substances include alpha-
tocopherol, lycopene, resveratrol (red grapes, red wine, peanuts and soy), sul-foraphanes
(broccoli), catechins (green tea), allicin and allium (garlic), curcumin (turmeric) and hypericin
(St John’s Wort).
Hot spices may disturb sleep. Tabasco and mustard in the evening may reduce slow wave and
reduce total time awake and increase time to fall asleep. The spicy food in the evening elevated
body temperature during the first sleep cycle, which explains probably some of the effects of
capsaicin on sleep. [37]
6. Free radicals, oxidative stress and sleep
Increasing evidence associates sleep deprivation and sleep-related disorders with oxidative
stress. Oxidative metabolism and energy production in the body generate free radicals and
nonradical derivatives of oxygen and of nitrogen [38]. Normally, the mitochondrial respiratory
chain generates a low level of free radicals during the process of making ATP. These free
radicals, in turn, may cause further damage to the mtDNA creating a vicious cycle of damage
and free radical production. It's unclear exactly how large a role the generation of free radicals
plays in causing or worsening the symptoms of mitochondrial disease. Antioxidants, usually
in the form of vitamins or trace elements, help neutralize free radicals. Although these products
are involved in normal cell regulation and signal transduction, an imbalance between their
generation and the antioxidant defense system results in oxidative stress. At the cellular level,
the stress response can be initiated by external environmental factors that cause damage to
biological macromolecules including lipids, proteins, and nucleic acids [39]. Oxidative stress
in sleep apnea is thought to be produced by hypoxic events and by hypoxia-reperfusion injury,
and in this way it contributes to cardiovascular complications and inflammatory processes [40,
41]. A role for disrupted sleep itself in the metabolic complications of sleep apnea has been
implied by some of the evidence but not fully explored [42]. Ramanathan et al. [43] reported
a significant decrease in superoxide dismutase (SOD) activity in the hippocampus and brain
stem, but not in the cerebral cortex, hypothalamus, or cerebellum in rats sleep deprived for 5–
11 days.
7. Prostaglandins and sleep
Prostaglandins (PGs) are synthesized from arachidonic acid by activated cyclo-oxygenase
(COX) in response to various stimuli in various types of cells. When synthesized, PGs are
immediately released and exert their actions on cells in the vicinity of their synthesis [44]. PGs
act in many parts of the body, including the reproductive system, the nervous system, the
cardiovascular system, the immune system and gastrointestinal system [45]. Due to their
diverse biological activity, there is potential for prostaglandin analogs (prostanoids) to
function as effective therapeutic agents.
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Sleep, a complex phenomenon, is not merely the result of physical fatigue or decrease in
activity; instead it is a complicated behavioural state requiring the integration of several
neuronal processes. Prostaglandins (PGs) are ubiquitously distributed in mammalian tissues,
exerting a variety of physiological and pathological effects such as disaggregation of blood
platelets [46], relaxation of smooth muscle [47] and pain and inflammation [48]. It is generally
accepted that PGD2 is one of the major PGs unique to the CNS, when compared to the relatively
low concentrations present in peripheral tissue [49]. Studies have revealed a variety of
endogenous substances that convincingly induce sleep. Among the multitude of sleep-
promoting substances, PGD2 has been described as a somnolence promoting substance in the
adult rat by acting on the traditional sleep centres of the VLPO area. PGD2 is produced from
PGH2 precursor by enzyme PGDS that is predominately synthesised in the leptomeningeal
layers and CP of the brain.
Prostaglandin D2 (PGD2) is a biologically active primary prostaglandin and a common
product of arachidonic metabolism in mammals. As a major eicosanoid product of mast cells
PGD2 is released in large quantities during allergic and asthmatic anaphylaxis. Several studies
have reported a crucial role for the prostaglandin D system in sleep regulation. This PGD2
accumulates in the cerebrospinal fluid (CSF), where it induces physiologic sleep in rats and
humans. PGD2 and PGE2 are found in high concentrations in the hypothalamus compared to
other regional areas of the brain [50, 51]. In addition, marked elevations of endogenous PGD2
concentrations in CSF occur in patients who suffer African sleeping sickness [52]. Continuous
infusion of PGD, into the lateral cerebral ventricle of monkeys during the diurnal period
induced a sleep pattern similar to physiological night sleep [53]. It is involved in the regulation
of reducing body temperature in sleep [54]. It is also produced in the brain via an alternative
pathway involving a soluble, secreted PGD-synthase also known as β-trace [55]. PGD2 acts in
the central nervous system in sleep induction and lowering of body temperature [51].Further
pharmacological actions include inhibition of platelet aggregation and relaxation of vascular
smooth muscle [56].
8. Glutathione and sleep
Glutathione is a tripeptide (gamma-glutamylcysteinylglycine) that performs many vital
functions in every cell of the body [57]. It is present in two forms in the body; in a “reduced
(GSH)” or an “oxidized (GSSG)” form. The majority of glutathione in the body is present in
its reduced form because this is the only way it can perform its critical role. Certain tissues are
more susceptible to GSH depletion than others. The reduced form of glutathione is the most
active form and is found in healthy cells. GSH plays an important role in the protection of cells
against damage from free radicals and other electrophiles. Several steps in the metabolism of
arachidonic acid may be normally regulated by GSH-enzymes [58]. It was an early observation
that GSH may function as a chemical cofactor or coenzyme in the formation of some PGs,
particularly PGEs [59]. Measuring glutathione levels in specific areas of the brain of sleep-
deprived animals reveals that the thalamus and hypothalamus are particularly susceptible
[60]. It is essential for detoxifying cells and this process is more active during sleep [61]. The
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vulnerability of these tissues may contribute to some of the functional effects of sleep depri‐
vation. The relationship between Glutathione (GSH) and sleep has been shown that it defends
the cells from destructive agents such as free radicals, chemical toxins, and heavy metals that
constantly assault the cells and inhibit their optimum function, causing disease and acceler‐
ating the aging process. Studies have shown that sleep deprived animals have lower gluta‐
thione levels in certain parts of the brain. The two brain areas involved in sleep are the thalamus
and hypothalamus. These areas are particularly vulnerable to glutathione depletion and can
lead to sleeping problems [60]. It has been reported that GSH is the only antioxidant that does
not become a free radical itself after donating a free electron [62]. Further research suggested
that high blood GSH concentrations correlates with long lifespan both in animals and humans
[63]. Mancuso et al [64] observed that GSH levels were lower in patients with OSAS than in
controls and suggests that antioxidant defences are impaired in patients with Obstructive sleep
apnea syndrome (OSAS). Recently, Ntalapascha et al (2012) reported that overnight changes
(%) in plasma biomarkers were significantly different between OSAS and controls for GSH/
GSSG, controls had increased GSH levels overnight whereas OSAS did not.
9. Dietary nutrients and sleep
In a recent large survey on more than 4500 people the association of many different nutrients
to sleep were studied. [66] The nutrients associated with difficulty falling asleep in order of
importance were lack of alpha carotene, lack of selenium, lack of dodecanoic acid, lack of
calcium and increased hexadecanoic acid. [66]Difficulty maintaining sleep was associated with
increased use of salt, less butanoic acid, less carbohydrates, less dodecanoic acid, less vitamin
D, less lycopene, more hexanoic acid and more moisture. Non-restorative sleep was associated
with more butaneoic acid less calcium, less vitamin C, less plain water, more moisture and
more cholesterol. In the same survey increased daytime sleepiness was associated more
moisture, more theobromine (see above for caffeine), less potassium and less plain water. [66]
10. Vitamins and minerals and sleep
Management of sleep disturbances combines nonpharmacologic and pharmacologic ap‐
proaches individualized for the patient. According to the International Classification of Sleep
Disorders (ICSD-2, 2005) [67] there are around 90 distinct sleep disorders. The cumulative
effects of sleep loss and sleep disorders have been associated with a wide range of deleterious
health consequences including an increased risk of hypertension, diabetes, obesity, depression,
heart attack, stroke and nutritional status of an individual could play a major role on sleep
quality. Observational studies have shown a link between sleep [68] and vitamins and
minerals, whether taken in combination or individually, are the most frequently consumed
dietary supplements among people today. Unlike other dietary supplement ingredients,
vitamins and certain minerals are considered essential nutrients for which standards of
adequacy are needed.
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10.1. Vitamins B
B vitamins are essential micronutrients and have many important functions in the body. The
B vitamins generally are coenzymes in the energy metabolism in the body. They are needed
for the syntheses and release of certain neurotransmitters and neurohormones that are
involved in the regulation of sleep and the circadian cycle. B vitamins have been advanced as
a preventive for insomnia based on research that suggests deficiencies in vitamin B6 promote
psychological distress and ensuing sleep disturbance [69]. Folic acid and vitamin B12 are both
B vitamins. Folic acid is often used in combination with other B vitamins [70]. Although the
direct link between vitamins and insomnia is unclear, there are studies that show an association
between vitamins and sleep disorders.
10.2. Vitamin B12, B6 and Folic Acid
Vitamin B12 deficiency has been linked to various neuropsychiatric disorders including slow
cerebration; confusion; memory changes; delirium, with or without hallucinations and/or
delusions; depression; acute psychotic states; sleep, and reversible manic and schizophreni‐
form states affective illness [71, 72]. It has been shown that depressed subjects have low serum
vitamin B12 levels [73]. It has been reported that high levels of vitamin B12 are associated with
good treatment outcome in patients with MDD [74]. However, others did not found any
association [75]. It has been reported that both folate and vitamin B12 are essential in several
metabolic pathways in the central nervous system, and their metabolism is intimately con‐
nected [76]. A deficiency of either vitamin causes impaired methylation in the central nervous
system and may result in neurological and psychiatric disease that becomes irreversible if not
treated properly [71]. Furthermore, vitamin B12 has been shown to modulate human melatonin
secretion [77]. Vitamin B6 is involved in the same metabolic pathways in the central nervous
system as vitamin B12 and folate. Earlier studies found a low level of plasma vitamin B6
associated with symptoms of depression [78]. Other reported that vitamin B6 supplementation
has positive effects on memory performance, but not on mood [79].
10.3. Vitamin D
Vitamin D is a group of fat-soluble prohormones synthesised in response to sunlight. The major
source of vitamin D in humans is exposure to UV radiation. The active form of vitamin D in
the body is 1,25-dihydroxyvitamin D, or calcitriol. Vitamin D has received a great deal of
attention recently. It has long been recognized as primarily a regulator of calcium and
phosphorus, helping to protect bone density. In recent years, however, our understanding of
the functions of Vitamin D in the body has expanded with numerous health outcomes. Vitamin
D is now understood to play an important role in metabolic and immune system functions.
Vitamin D deficiency has been linked to a number of illnesses and chronic conditions, including
high blood pressure, diabetes; metabolic syndrome, pulmonary disease, and chronic pain.
Vitamin D supplementation during winter improve mood in healthy volunteers [80]. One
possible mechanism of action is that serum 1,25-dihydroxyvitamin D levels affect the levels of
serotonin in the hypothalamus [81] and thereby enhance the synthesis and transmission of
serotonin, leading to improvement in mood. Novel associations between sleep symptoms and
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vitamin D have been reported [82, 83, 84]. Further evidence suggest that low vitamin D levels
increase the risk for autoimmune disease, chronic rhinitis, tonsillar hypertrophy, cardiovas‐
cular disease, and diabetes [85]. McCarty et al. [86] reported that persistent inadequacy of
vitamin D may also increase the risk for obstructive sleep apnea via promotion of adenoton‐
sillar hypertrophy, airway muscle myopathy, and/or chronic rhinitis.
10.4. Vitamin A
Vitamin A is the parent compound of retinoid, which regulate gene transcription by binding
to nuclear retinoid receptors. It is involved in immune function, vision, reproduction, and
cellular communication. Vitamin A is very important for the mucous membranes as it is needed
for the proper production of mucopolysaccharides, which help to protect against infections.
Barceló et al. [87], reported that patients with obstructive sleep apnoea syndrome have a
decreased antioxidant capacity of vitamin A and E levels. Study of sleep in mouse models of
ageing, Ransom et al [88] showed further clues as to the involvement of vitamin A in the
regulation of delta oscillations. It has been suggested that retinoid signalling pathways are
important for adult neural function in health and disease [89]. A definitive role for vitamin A
signalling however is evident in the regulation of delta oscillations. This was first proposed
by Maret et al. [90], who observed that the relative contribution of the delta wave to slow move
sleep (SWS) is determined by the RA receptor RARb1. Moreover, vitamin A deficiency is
known to significantly reduce the power of the delta oscillation in mice [91].
10.5. Vitamin C
Vitamin C prevents some oxidative damage brought on by endurance exercise to the fat and
muscle tissue. It is required for the transformation of dopamine into noradrenalin [92], and
the function of this vitamin has been suggested to extend to neuromodulation of dopamine,
regulation of acetylcholine and catecholamine release, and glutamate and GABA mediated
neurotransmission [93]. Sleep symptoms are associated with weight gain and cardio metabolic
disease. The potential role of diet including vitamin C that was associated independently with
non-restorative sleep has been reported [82, 94], they suggest a novel associations between
sleep symptoms and diet/metabolism, potentially explaining associations between sleep and
cardiometabolic disease. Singh et al. [95], supplementing OSA patients with vitamins E and C
concluded that that antioxidant treatment (oral vitamin E and C) reduced oxidative stress in
OSA patients. Furthermore, decreased levels of antioxidants (superoxide dismutase, catalase,
glutathione and homocysteine, as well as vitamins E, C, B11 and B12) and lower performance
on the neuropsychological tasks were observed in patients with obstructive sleep apnea [96].
The authors suggest that an imbalance between antioxidants and pro-oxidants may contribute
to neuropsychological alterations in this patient population. In restless leg syndrome (RLS),
vitamins C and E and their combination are used as safe and effective treatments for reducing
the severity of RLS in hemodialysis patients [97]. Ascorbic acid and sodium-dependent vitamin
C transporters (SVCT) have been shown to have important functions in the peripheral nervous
system (PNS) [98].
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10.6. Vitamin E
Vitamin E has active ingredients of tocopherols and tocotrienols. It exists in eight different
natural forms, all of which have antioxidant properties When supplemented it may reduce
damage to cell DNA and cell and it has neuroprotective effect on the brain. Vitamin E may
stabilize peripheral blood circulation, suppressing abrupt deformation of vessels [99], accel‐
eration of blood flow in vessels would increase the pressure of blood on the vessel walls, and
subtle changes in vessel tension or shape might stimulate nerve fibres that are in anatomical
proximity to the vessels [99]. Vitamin E normalized chronic sleep deprivation-induced
reduction in the hippocampus GSH/GSSG ratio, and activity of catalase, super oxide dismutase
(SOD), and glutathione peroxidase (GPx) [100]. Decreased levels of antioxidants and lower
performance on the neuropsychological tasks were observed in patients with obstructive sleep
apnea [10]1. This study suggests that an imbalance between antioxidants and pro-oxidants may
contribute to neuropsychological alterations in this patient population.During eight-year
follow-up study to investigate the link between vitamin E, namely α-tocopherol, and memory
disorders, it was found that higher total serum levels of vitamin E, and higher levels of γ-
tocopherol, β-tocotrienol and total tocotrienols in particular, seemed to protect against
memory disorders [102]. Their results show that the entire vitamin E family plays a role in
memory processes. Accordingly, measuring the levels of vitamin E from serum is the most
reliable way to determine whether they are sufficiently high. Limited research indicates that
supplemental vitamin E may reduce symptom occurrence in restless leg syndrome [103].
10.7. L-carnitine and Sleep
Acetyl-L-carnitine (ALC) is a naturally occurring compound that facilitates the transport of
fatty acids into mitochondria for β-oxidation [104]. Acetyl-L-carnitine can enter the brain, and
the acetyl group helps form acetylcholine, an important neurotransmitter. L-carnitine enhan‐
ces resistance to oxidative stress by reducing DNA damage in Ataxia telangiectasia cells [105].
Positive results were seen in carnitine supplementation in depression, dysthymia, mental and
physical energy, with less fatigue, muscle pain, and sleep problems [106,107,108]. Muscle
weakness and hepatic dysfunction can also been noted [109]. Supplementation of carnitine has
also been shown to be a mood elevator in the elderly [110]. Acetyl L-Carnitine helps the brain
form acetylcholine, a neurotransmitter needed for memory and thinking [111].
Evidence for the effectiveness of L-carnitine in attention deficit and hyperactivity disorder
(ADHD) has been studied [112]. Other studies in animals and human have shown that a
combination of acetyl-L-carnitine and alpha-lipoic acid reversed many of the signs of aging
and restored both physical and mental vigor. Low levels of carnitine are associated with a
higher frequency of fragmented wakefulness [113].
L-Carnitine has been demonstrated to be therapeutic for individuals with narcolepsy. A recent
study investigated the contribution of a gene polymorphism found in narcolepsy called
CPT1B, which is important in fatty acid oxidation [114]. They found that individuals with
narcolepsy had very low levels of serum acylcarnitine [115]. L-carnitine was given (510 mg/
day) to patients with narcolepsy it was revealed that total time for dozing off during daytime
in narcolepsy patients, the primary endpoint, was significantly decreased by L-carnitine
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supplementation compared with placebo [114]. Although narcolepsy is a rather rare disorder,
daytime sleepiness is not. It is possible that low levels of carnitine could be a cause of fatigue
and daytime sleepiness. For example, low serum carnitine levels have been observed in
patients with chronic fatigue syndrome (CFS) – a clinically defined condition characterized by
severe disabling fatigue and a combination of symptoms, such as musculoskeletal pain,
difficulty in concentration and sleep disturbances.
L-carnitine supplementation also increased serum carnitine levels and reduced serum
triglycerides concentration indicating improvement in the burning of fat as energy. Other
researchers found that ALC treatment reduced symptoms of depression in older people [116].
It also improved dysthymia, a milder form of depression, about as well as a common medi‐
cation. Several studies show that ALC may help improve certain behaviours in boys with
fragile X syndrome (FXS), such as their social skills and hyperactivity. The study has linked
ALC with less pain or less-intense pain in people with nerve problems from these causes. ALC
is a compound of great interest in various neurological disorders such as in treating Alzheim‐
er’s dementia, HIV-infection, diabetic neuropathies and aging [117,118,119,120]. A decrease of
sleep disorders, a muscle discomfort, and of the prolonged fatigue after exercise has also been
shown [121]. Carnitine supplementation could be helpful in mitochondrial disorders as the
sleep problems are commonly reported in patients with mitochondrial myopathies [122,123].
11. Fatty acids
There is a growing consensus that omega-3 fatty acids are essential nutrients for humans. Much
of the evidence is based on physiological measurements such as neurological development
and visual acuity. To better understand why this class of polyunsaturated fatty acids is
required, we must determine the biochemical basis for the essentiality. Of the eight fatty acids
that comprise the omega-3 metabolic pathway, the two that are most likely to have essential
biochemical functions are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
EPA can be converted to prostaglandins, thromboxanes and lipoxygenase products [124].
However, no essential role for these EPA-metabolites has been reported, and it seems unlikely
that the formation of these products is the reason that omega-3 fatty acids are essential. When
elevated amounts of EPA are available, the incorporation of arachidonic acid (AA) into cell
phospholipids and its conversion to eicosanoid mediators is reduced. Thus, EPA acts as a
competitive inhibitor of AA, and this probably accounts for some of the beneficial effects of
omega-3 fatty acids in the treatment of cardiovascular and inflammatory diseases. While the
possibility that EPA is essential in order to modulate the effects of AA cannot be ruled out, the
amounts ordinarily present in the plasma and tissues probably are too low to competitively
inhibit the actions of AA. Therefore, modulation of AA metabolism is more likely to be a
pharmacological effect of omega-3 fatty acid supplements rather than an essential physiolog‐
ical function.
The basis for considering DHA as the biochemically essential omega-3 component is much
more compelling. DHA is the most abundant omega-3 fatty acid in most tissues, and it is
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present in large amounts in the brain and retina. DHA is the omega-3 fatty acid required for
normal development of the nervous system and optimum visual acuity. Furthermore, when
an omega-3 fatty acid deficiency exists, the body compensates by replacing it with the
corresponding fatty acid of the omega-6 series, omega-6 docosapentaenoic acid (DPAn-6).
These findings strongly suggest that DHA has an essential biochemical function. The most
likely possibility is a membrane structural effect involving the packing of phospholipid head
groups or the interaction of the lipid domains with membrane proteins. The lipids that contain
the highest percentages of DHA are ethanolamine plasmalogen, phosphatidylethanolamine
and phosphatidylserine. Therefore, it is likely that the function of DHA involves the metabo‐
lism, trafficking or physical properties of these phospholipids. Other possibilities that must be
considered include the conversion of DHA to a lipid mediator, binding of DHA to a nuclear
receptor that regulates gene expression, or formation of a DHA-centered free radical. It is
thought that omega-3 fatty acids in fish oils may reduce inflammation of the brain and play a
part in brain development and nerve cell regeneration [125]. However, there has been mixed
evidence as to the benefits of omega-3 fish oils on the brain and whether they may protect
against memory decline and dementia [126,127]. A combination of omega-3 fatty acid and
vitamin B12 enriched diet may exert beneficial effects on synaptic plasticity and cognition,
which may prove beneficial for mental health, particularly in preventing neurocognitive
disorders [128].
A central question concerning the essentiality of omega-3 fatty acids is why DHA rather than
the corresponding member of the omega-6 series, DPAn-6, fulfils this purpose. The usual
Western diet contains 10-to 20-times more omega-6 fatty acid, and the same metabolic pathway
is utilized by both fatty acid classes. One possibility is that DHA is utilized more efficiently
than DPAn-6.
However, studies with neural cells in culture indicate that there is no appreciable difference
in the uptake, retention or incorporation into phospholipids of DHA as compared with
DPAn-6. While more detailed measurements may reveal a functional difference between DHA
and DPAn-6, no such evidence is currently available. This suggests that DHA is utilized rather
than DPAn-6 because it is more available to the tissues. Although the absolute amounts of
these fatty acids in the plasma lipids are very small, there ordinarily is about five-times more
DHA than DPAn-6. Furthermore, the main product formed by cultured astrocytes from
omega-3 fatty acid precursors is DHA, whereas the main omega-6 product is AA. Astrocytes
are the site where most of the polyunsaturated fatty acid precursors are elongated and
desaturated in the brain. Thus, much more DHA than DPAn-6 appears to be available in the
central nervous system [129].
11.1. Fish oils and omega-3 fatty acids
Polyunsaturated fatty acids (PUFA) are essential fatty acids in many mammals including
humans. Both docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are omega-3
acids and they may also be obtained by eating fish oils. There is some evidence showing that
a reduced amount of ingested omega-3 fatty acids is associated with fatigue, depression and
problems of attention. [130-136] A sufficient amount of PUFA from food is necessary for health
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and well-being. Fatty fish is the best source of omga-3 acids. One hundred grams of salmon
contains about 1000 mg of omega-3 acids and 100 grams of herring contains about 2000 mg.
White fish meat contains much less of these essential fatty acids than fish with fatty meat.
Omega-3 acids have been tested in the treatment of subjects with attention deficit disorder and
in subjects with depression, female subjects with borderline personality, fatigue in multiple
sclerosis, memory disturbances, dementia and some other neuropsychiatric diseases. Some
randomized controlled studies have shown that omega-3 fatty acids may ameliorate mental
functions, but they are also conflicting results. [130 – 137]
There is only little evidence showing that essential fatty acids may modulate sleep. In a small
studied eight children. They were fed by total parenteral nutrition without essential lipids and
seven other children who received a daily supplement of essential lipids in their parenteral
nutrition. Slow wave sleep was significantly decreased in the group of children who did not
receive fatty acids as compared to those who did. [138]No randomized clinical trials have been
done in primary insomnia or in central hypersomnias.
12. Trace elements and sleep
Certain nutritional imbalances appear to influence sleep quality and play an important role
in the maintenance of redox homeostasis:
12.1. Zinc
Zinc is an important cofactor for metabolism relevant to neurotransmitters, prostaglandins,
and melatonin, and indirectly affects dopamine metabolism [139]. The role of zinc is thought
to transduce oxidative stress and other signals converging at the production of nitric oxide
into an specific intracellular response, suggesting an intriguing task of "signal transducer"
[140]. It contributes to structure and function of brain [141], and low levels of zinc can cause a
range of symptoms including hyperactivity and jitters [142]. Epidemiological studies on the
influence of zinc/diet and lifestyle implications on degenerative disease and in particular on
autism has been documented. Interestingly, antioxidant and micronutrients in the diet, such
as zinc, influence the development and function of immune cells, the activity of stress-related
proteins and antioxidant enzymes and help to maintain genomic integrity and stability [143,
144]. Zinc is included in many enzymatic processes. [145, 146] In CNS zinc is abundant in the
so-called “zinc containing” synapses of glutamatergic neurons. Such neurons are located
mainly in the prefrontal lobe. Frontal dysfunction may follow lack of zinc. On the other hand,
bivalent zinc may cause excitotoxic damage. Also other minerals (e.g., magnesium, manga‐
nese) are important for proper functioning of the CNS. [145, 147, 148]
Zinc was shown to play a role in inducing the synthesis of metallothionein that acts as a
scavenger  of  metals  and  free  radicals  [149].  It  is  necessary  for  100  different  metalloen‐
zymes and metal–enzyme complexes [150], many of them in the central nervous system.
Zinc supplementation of young children in low income countries improves their neurophy‐
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siological  performance  [151],  also  in  combination  with  iron  supplements  [152].  Some
behavioural abnormalities in adults also seem to respond favourably to zinc supplementa‐
tion, such as mood changes, emotional lability, anorexia, irritability and depression [153].
All  these  physiological  functions  occur  through  the  action  of  proteins  involved  in  the
regulation of zinc homeostasis, such as metallothioneins, which bind zinc with high affinity
but, at the same time, release free zinc ions in response to oxidative/nitrosative stress to
modulate the expression of zinc-dependent genes and to activate antioxidant enzymes and
impact immune response [154].
12.1.1. Antioxidant properties of zinc
Zinc deficiency is difficult to evaluate due to the lack of sensitive and specific biomarkers [155].
Studies observed improved neurophysiologic performance, positive growth response, and
significantly reduced mortality and morbidity with zinc supplementation in Chinese children
[156]. Zinc effect on immune/inflammation responses has been reported [157]. It has been
suggested that the bioavailability of zinc ion regulates the expression of pro-inflammatory
cytokines and heat shock proteins such as IL-6, TNF-α and Hsp70 [158], and affects TH1/TH2
balance [159]. Several mechanisms could be involved in antioxidant function of zinc. One, zinc
may protect protein sulfhydryl groups from oxidative modification by influencing the
conformation and reducing potential of thiol groups. Since the sulfhydryl groups are required
for the catalytic activities of several enzymes, zinc protects the enzyme’s activity from oxidative
inactivation.
Second, zinc may antagonize the activity of transition metals such as iron and copper. A
number of studies have linked RLS to deficiencies of dopamine and iron. The disorder may
result from inefficient processing of iron in certain brain cells [160]. A decrease in iron levels
in the substantia nigra and, to a lesser degree, in idiopathic RLS patients was reported [161].
Ferritin levels were lower in cerebrospinal fluid, whereas transferrin levels were higher in
patients with RLS compared to controls [162]. Connor et al. [163] found that receptors which
help cells absorb iron are abnormally regulated in cells that produce the nerve-signaling
chemical dopamine. Zago and Oteiza [164] showed that zinc may compete with copper and
iron ions and prevent transition metal mediated oxidative modifications, and third mechanism
for the antioxidant property of zinc is that zinc may reduce oxidative damage indirectly by
modulating antioxidant defence including (a) enzymes which catalytically remove free
radicals and reactive species, like superoxide dismutase, catalase, and glutathione peroxidase;
(b) proteins which minimize the availability of pro-oxidants, like transferrins, ceruloplasmin
and metallothioneins; (c) low-molecular-mass ROS and RNS scavengers, like glutathione,
ascorbic acid, uric acid and alpha-tocopherol.
Antioxidant  enzymes  such  as  CuZn  superoxide  dismutase  (CuZnSOD),  glutathione
peroxidase  (GPX)  and  catalase  are  located  in  different  cellular  compartments  and  have
different functions. Mice defective in CuZnSOD develop neurological damage and cancer
at an accelerated rate as they age [165]. GPX-1 knockout mice are much more sensitive to
paraquat toxicity than the wide type mice [166].  One human study done in a European
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population observed that the erythrocyte SOD activities were negatively associated with
the plasma zinc concentrations, and positively associated with age. They also observed that
the plasma catalase and GPX activities were similar among groups having different plasma
zinc concentrations [158].
Zinc is one of the micronutrients involved in behavior, learning and mental functions. Zinc
is necessary for proper immune function, and to create protein and DNA. The administra‐
tion of nightly melatonin, magnesium, and zinc appears to improve the quality of sleep
and the  quality  of  life  in  long-term care  facility  residents  with  primary insomnia  [167].
micronutrients  such  as  zinc  and  magnesium may  play  a  role  in  facilitating  sleep.  Zinc
exhibits an antidepressant-like activity, as stated in a preclinical model of depression [168].
Significant clinical correlates were shown by Sowa-Kućma et al. [169] related to its action
as an antagonist of the glutamate/N-methyl-D-aspartate receptor. Magnesium has benefi‐
cial  effects  on  mood and is  crucial,  together  with  zinc,  in  the  endogenous  synthesis  of
melatonin [170].
Zinc  is  an  essential  bio-element,  which  plays  a  fundamental  role  in  a  wide  range  of
biochemical  processes.  This  metal  is  a  major  component  of  various  proteins  and  is  an
important modulator of the mammalian immune and nervous systems [171]. Zinc is one
of the mineral that has such a wide application in human health. A deficiency may result
in sleep disturbances. Most sleeping pills, especially when taken over long periods of time,
can have multiple side effects. Alterations of blood zinc homeostasis may accompany mood
disturbances as well as affect functions of the immune system [172]. Recent data indicate
that  alterations  in  zinc  (a  natural  modulator  of  amino-acidergic  neurotransmission)
homeostasis  may contribute  to  mood disorders  and may be involved in antidepressant-
like actions in laboratory models [171].
12.2. Iron
Iron has an important role in many enzymatic processes. Sufficient iron in the CNS is necessary
for normal functioning of the dopamine system. Iron has an effect on functioning of the
dopamine receptors. Tyrosine hydroxlase regulates dopamine synthesis. Iron and tetrahydro‐
biopterin are cofactors of tyrosinehydroxylase. Iron is also linked to functions of GABA,
serotonin and opidiod-peptides. In experimental cell cultures dopaminergic cells of the
substantia nigra can be destroyed by chelation of iron by desferoxamine. Adding opioids in
these cell cultures is protective. Iron also has a catalytic effect in oxidative mechanisms of the
CNS and epilepsy [173]. Measuring serum ferritin and soluble transferring receptor from a
venous blood sample allows estimation of tissue iron levels. In restless legs syndrome S-ferritin
is often low, in which case, giving iron per os, or intravenously in more severe cases, should
be part of the treatment.
In patients with RLS 45 μg/L is usually used as a limit when one should consider giving iron
supplement even if hemoglobin is normal. Usually the soluble transferrin receptor values are
also low. Iron should be gioven as Fe2+(bivalent iron) together with vitamin C to increase
absorption of iron from the gut. If ferritin levels do not rise and the symptoms are bothersome
Nutrition, Sleep and Sleep Disorders – Relations of Some Food Constituents and Sleep
http://dx.doi.org/10.5772/58345
205
one might consider IV iron. Iron dextrane should be avoided because of potential risks but
safe formulations exist, such as Venofer®. Several studies have already shown the benefits of
IV iron starting from the early experiences from Sweden in the 1950’s. [174, 175]
Yehuda has noted that in young children sleep disturbances,  fatigue and possible learn‐
ing disturbances may be related to iron deficiency early in life. These findings require further
studies. [176] To determine if there is a relationship between low serum ferritin and sleep
disturbance  in  children  with  autism spectrum disorder,  an  eight-week  open-label  treat‐
ment  trial  on 33 children with oral  iron supplementation has been done.  Seventy-seven
percent  had  restless  sleep  at  baseline,  which  improved  significantly  with  iron  therapy,
suggesting a relationship between sleep disturbance and iron deficiency in children with
autism  spectrum  disorder.  Sixty-nine  percent  of  preschoolers  and  35%  of  school-aged
children had insufficient dietary iron intake. Mean ferritin increased significantly (16 μg/L
to 29 μg/L). It may be that children with autism spectrum disorder should be screened for
iron deficiency. [177]
Kuhn et al. studied the effects of five days of sleep deprivation on the circadian rhythm of
serum iron in a group of six healthy male volunteers. The results were compared with a
control group of five individuals, whose normal sleep cycle was preserved, but whose daily
regimen was otherwise identical with the sleep deprivation group. Their biorhythm was
analyzed using cosinor  analysis.  Sleep deprivation markedly reduced the  mean level  of
iron, diminished the absolute and relative amplitude of oscillations, disturbed the shape of
the daily course of  serum iron and gradually decreased the computative acrophase,  i.e.,
shortened the period of rhythm. Forty-eight hours of recovery resulted in only a partial
normalization  of  all  the  observed  changes.  The  potential  mechanisms  of  the  observed
changes are discussed. [178]
12.3. Copper
Copper acts as a cofactor in many enzymatic processes including ceruloplasmin, monoami‐
nexidases, cytochromoxidase, and superoxide dismutase. The largest part of copper (96%) is
binded into cerluloplasmin and ferro-oxidase, which is needed in many phases of iron
metabolism. [179] Lack of copper can manifest as neutropenia, microcytic anemia, growth
disturbances or slowing of erythropoiesis. Large amount of vitamine C, zinc, iron and cysteine
worsen the absorption of copper from the gut. Menkes syndrome is an example of a genetic
disturbance of copper metabolism causing deficiency of copper. Wilson’s disease is an
autosomal recessive disease that causes accumulation of copper in the liver and brain [180]. It
is practically impossible to have too much copper from a normal diet. Lack of copper may
follow poor diet or excessive consumption of zinc tablets.
12.4. Selenium
Selenium (Se) is a natural antioxidant which delays the oxidation of polyunsaturated fatty
acids  and  preserves  the  elasticity  of  tissue  [181,  182].  Se  is  an  essential  component  of
thioredoxinreductase and glutathione peroxidases, with strong antioxidative and antiinflam‐
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matory properties, and there is particular interest in the potential of Se to modulate oxidative
stress and induce anticancer activity [183, 184]. Selenium is required for the production of
certain prostaglandins which decrease platelet aggregation [185]. Selenium deficiency has
been  linked  to  adverse  mood  states  [183].  Several  lines  of  evidence  have  shown  that
selenium  is  crucially  important  in  the  maintenance  and  modulation  of  different  brain
functions. [186-189] Selenium may have some role in regulation of sleep and in develop‐
ment of insomnia as lack of selenium was statistically significantly associated with difficulty
falling asleep in a recent large survey. [130]
Selenium supplementation together with other vitamins has been found beneficial in the
treatment of mood lability [190, 191].In synergy with vitamin E, selenium promotes normal
growth and fertility, and improves the function of certain energy producing cells [192, 193].
Also,  selenium also plays a role in your immune system and thyroid function and may
contribute to sleeping abnormalities. Infusion of selective inhibitors of PGDS, e.g., tetrava‐
lent  selenium  compounds,  reversibly,  time-and  dose-dependently  inhibited  both  non-
rapid eye movement (NREM) and rapid eye movement (REM) sleep during the daytime
[194], which shows that PGDS plays a crucial role in the regulation of physiological sleep.
Selenium deficit may result in severe disorders [195, 196], including mood disorders. Gosney
et al [197] reported the effects of micronutrient supplementation on mood in nursing home
residents; selenium supplementation was directly correlated with decreases in depression
scores and increases in serum levels. Supplementation with selenium resulted in reduced
serum thyroid hormone T4 and increased serum thyroid hormone T3, suggesting that the
additional selenium helped the rather boring T4 become the metabolically active T3. Effects
of  sleep  deprivation  (SD)  and selenium (Se)  on  wound healing  were  studied  [198],  the
number of fibroblasts and capillary vessels were higher in control and Se groups than in
sleep deprivation groups, and the number of PNLs and the radiolabeled polyvalent IgG
levels were higher in SD groups than in control and Se groups. OSA patients had lower
concentrations of plasma Zn and erythrocyte Se [199]. Furthermore, the effect of selenium
on restless leg syndrome treatment was studied [200, 201], selenium supplementation would
be an alternative treatment in improvement of RLS symptoms.
13. In summary
Little is still known about the effects of different constituents of meals on sleep. There is
evidence that a heavy lunch and rapidly absorbing carbohydrates enhance sleepiness in the
afternoon. This may add to daytime sleepiness and for that reason they should be avoided
when one wants to avoid fatigue. On the contrary, a light evening meal which is rich in
carbohydrates may help one to fall asleep in the evening. The relationships between the enteric
nervous system and CNS, and different roles of dietary nutrients and CNS need to be studied
much more in the future.
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